Neurocrine Biosciences, Inc. (NBIX) Stock Price & How to Invest

Neurocrine Biosciences makes money primarily from Ingrezza (valbenazine), an oral VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease, which generated about $657 million in net product sales in Q1 2026, up roughly 20 percent year over year, with full-year 2026 guidance of about $2.7 to $2.8 billion. A second product, Crenessity (crinecerfont), launched for classic congenital adrenal hyperplasia and contributed about $153 million in Q1 2026, helping total quarterly revenue grow roughly 44 percent to about $815 million. The company is solidly profitable, reporting Q1 2026 net income near $198 million.

Founded in 1992 and based in San Diego, Neurocrine spent years as a clinical-stage company before Ingrezza's 2017 approval turned it into a commercial neuroscience franchise. It has since built a pipeline spanning psychiatry and neurology, headlined by NBI-1117568, a selective muscarinic M4 agonist for schizophrenia that produced positive Phase 2 data and has entered a Phase 3 registrational program, plus additional muscarinic compounds licensed from Nxera Pharma. In 2026 the company also agreed to acquire Soleno Therapeutics for roughly $2.9 billion, broadening its rare-disease commercial portfolio.

The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from new VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. CNS drug development is also high-risk, and a single Phase 3 miss for the muscarinic program or other pipeline candidates could sharply reset expectations. Large acquisitions like Soleno add integration and execution risk, and the stock can be volatile around trial readouts, label decisions, and guidance updates.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Neurocrine Biosciences, Inc.'s investor relations page or your broker.

• Revenue (TTM): ~$2.9 billion
• Ingrezza net sales (Q1 2026): ~$657 million
• Crenessity net sales (Q1 2026): ~$153 million
• Net income (Q1 2026): ~$198 million
• P/E ratio (TTM): ~25x
• Market cap: ~$16 billion

Figures are approximate and tied to the asOf date, drawn from Q1 2026 results and mid-2026 market data. Neurocrine trades at a trailing P/E near 25x, a premium to the broader biotech group that reflects its profitability and pipeline optionality. Total Q1 2026 revenue grew about 44 percent year over year to roughly $815 million as Crenessity scaled alongside Ingrezza.

These are the investment theses NBIX naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Other names that show up alongside NBIX in the same themes. Worth a look if you're thinking about diversification within a single thesis rather than concentration on one ticker.

There are three common ways to get NBIX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so NBIX sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where NBIX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Neurocrine today is a commercial-stage neuroscience company built around Ingrezza, which posted roughly $657 million in net sales in Q1 2026 and carries full-year guidance of about $2.7 to $2.8 billion, alongside a fast-ramping second product, Crenessity, and a deep central nervous system pipeline led by a muscarinic agonist for schizophrenia now in Phase 3. If you believe a single profitable franchise can fund genuine diversification into psychiatry and neurology, the question becomes sizing and overlap with biotech and healthcare you already own, not timing. The risk is concentration: most revenue still comes from one drug, and pipeline readouts in CNS are binary, so a single trial miss or new competitor can move the stock sharply.

Whether NBIX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NBIX a buy?, and where the stock could go from here in the NBIX stock forecast.

For income investors, whether NBIX pays a dividend and how the payout looks is covered in does NBIX pay a dividend? And to weigh NBIX against a peer, read the full side-by-side comparisons: NBIX vs REGN.